The susceptibility of mycobacteria to rifamide and rifampicin.
D000636:Aminosalicylic Acids / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology*; D003523:Cycloserine / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D005000:Ethionamide / Q000494:pharmacology; D006801:Humans; D007275:Injections, Intravenous; D007538:Isoniazid / Q000494:pharmacology; D007612:Kanamycin / Q000494:pharmacology; D009161:Mycobacterium / Q000187:drug effects; D009163:Mycobacterium bovis / Q000187:drug effects; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D011718:Pyrazinamide / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology*; D013307:Streptomycin / Q000494:pharmacology; D013882:Thiosemicarbazones / Q000494:pharmacology; D014756:Viomycin / Q000494:pharmacology
D000636:Aminosalicylic Acids; D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D013882:Thiosemicarbazones; D011718:Pyrazinamide; D007612:Kanamycin; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin; D014756:Viomycin